ReviewDiscover oncology2026
The functional roles and therapeutic potential of protein palmitoylation in hepatocellular carcinoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveProtein palmitoylation is a reversible lipid post-translational modification that influences protein stability, membrane association, and signal transduction. Increasing evidence indicates that dysregulated palmitoylation contributes to tumor development by altering the activity of oncogenes, tumor suppressors, transcription factors, and membrane proteins, as well as by reshaping the tumor microenvironment. However, the biological significance of this modification in hepatocellular carcinoma (HCC) has not yet been fully clarified. This review summarizes current knowledge of palmitoylation-mediated regulation in HCC and evaluates its potential as a therapeutic target.
methodsRelevant studies were identified through systematic searches of PubMed and Web of Science using keywords including "protein palmitoylation," "post-translational modification," "hepatocellular carcinoma," and "tumor therapy." Published evidence was analyzed to examine the roles of palmitoylation in HCC cell proliferation, apoptosis, migration, invasion, and associated signaling pathways.
resultsAccumulating evidence indicates that protein palmitoylation contributes to hepatocellular carcinoma progression by modulating the activity and localization of key signaling proteins, including Ras, AKT, and YAP. Through these regulatory effects, palmitoylation influences multiple oncogenic pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, Hippo/YAP, and STAT3 signaling. In addition, metabolic regulatory circuits, including the FASN-ZDHHC-20 and PHF2-SREBP1c axes, link lipid metabolism with palmitoylation-dependent signaling in HCC. Emerging pharmacological approaches targeting palmitoylation-related enzymes-such as palmitoyltransferases and depalmitoylases-have shown promising antitumor activity in preclinical studies.
conclusionProtein palmitoylation represents an important regulatory layer in hepatocellular carcinoma biology, integrating lipid metabolism with oncogenic signaling networks. Therapeutic strategies targeting enzymes that control palmitoylation dynamics may therefore offer new opportunities for HCC treatment. Future investigations should focus on defining the substrate specificity and regulatory mechanisms of individual ZDHHC enzymes, PATs, and depalmitoylases to facilitate the development of more selective therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.